Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Bladder Cancer

  Free Subscription


29.09.2025

1 Abdom Radiol (NY)
1 Acad Radiol
1 Anal Chem
1 Angew Chem Int Ed Engl
1 Ann Oncol
1 BJU Int
1 Bladder Cancer
1 Cancer Res Treat
1 Clin Genitourin Cancer
1 Crit Rev Oncol Hematol
1 Cureus
2 Curr Opin Urol
3 Eur Urol
4 Eur Urol Oncol
1 Eur Urol Open Sci
1 Expert Rev Mol Diagn
1 Front Cell Dev Biol
1 Future Sci OA
1 Gene
1 Hum Mutat
1 Int J Urol
1 J Am Soc Cytopathol
1 J Control Release
1 Oncologist
1 PLoS One
1 Radiologia (Engl Ed)
1 Target Oncol
1 Tissue Cell
1 Urol Oncol


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Abdom Radiol (NY)

  1. GUO E, Chen L, Xu L, Zhang D, et al
    Optimizing bladder magnetic resonance imaging: accelerating scan time and improving image quality through deep learning.
    Abdom Radiol (NY). 2025;50:4772-4782.
    PubMed         Abstract available


    Acad Radiol

  2. DU Y, Sui Y, Tao Y, Cao J, et al
    Comprehensive Assessment of Tumor Stromal Heterogeneity in Bladder Cancer by Deep Learning and Habitat Radiomics.
    Acad Radiol. 2025 Sep 22:S1076-6332(25)00799-8. doi: 10.1016/j.acra.2025.
    PubMed         Abstract available


    Anal Chem

  3. ZHANG T, Zhang H, Qi J, Jiang S, et al
    Hollow Dodecahedral Nanocages for Reliable Multi-Level Differentiation of Urological Cancers through Non-Invasive Metabolic Fingerprinting.
    Anal Chem. 2025;97:20622-20631.
    PubMed         Abstract available


    Angew Chem Int Ed Engl

  4. CHENG Y, Zhou K, Chen Y, Mei Y, et al
    Concurrent Ferroptosis and Pyroptosis Induced by a Dual-Organelle-Targeted Type I/II AIE Photosensitizer for Bladder Cancer Immunotherapy.
    Angew Chem Int Ed Engl. 2025 Sep 18:e202509783. doi: 10.1002/anie.202509783.
    PubMed         Abstract available


    Ann Oncol

  5. POWLES TB, Van der Heijden MS, Loriot Y, Bedke J, et al
    Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial.
    Ann Oncol. 2025;36:1212-1219.
    PubMed         Abstract available


    BJU Int

  6. KALEN E, Ginstman C, Liedberg F, Hagberg O, et al
    Incidence and risk factors for postoperative vaginal events following radical cystectomy for bladder cancer: a nationwide population-based study.
    BJU Int. 2025 Sep 20. doi: 10.1111/bju.70004.
    PubMed         Abstract available


    Bladder Cancer

  7. BUKAVINA L, Isali I, Parekh S, Psutka S, et al
    Genetic susceptibility and environmental risk factors in bladder cancer: Evidence from the UK biobank.
    Bladder Cancer. 2025;11:23523735251370863.
    PubMed         Abstract available


    Cancer Res Treat

  8. YING W, Li D, Feng N, Wei W, et al
    LncRNA DGUOK-AS1 Promotes Bladder Cancer Progression by Enhancing EFTUD2 Stability.
    Cancer Res Treat. 2025 Sep 18. doi: 10.4143/crt.2025.
    PubMed         Abstract available


    Clin Genitourin Cancer

  9. JUHASZ D, Csizmarik A, Varadi M, Bacso D, et al
    Lymphovascular Invasion is Predictive for Adjuvant Platinum Therapy Benefit in Urothelial Bladder Cancer.
    Clin Genitourin Cancer. 2025 Sep 1:102421. doi: 10.1016/j.clgc.2025.102421.
    PubMed         Abstract available


    Crit Rev Oncol Hematol

  10. TATAR AC, Loghin A, Nechifor-Boila A, Raicea A, et al
    IHC-based molecular classification in muscle-invasive urothelial bladder carcinoma: Prognostic and predictive value toward a clinically applicable IHC marker panel - A systematic review.
    Crit Rev Oncol Hematol. 2025;214:104868.
    PubMed         Abstract available


    Cureus

  11. YONG ZONG AT, Yap WK
    Global Research Trends in Bladder Cancer Biomarkers: A Bibliometric Analysis.
    Cureus. 2025;17:e90724.
    PubMed         Abstract available


    Curr Opin Urol

  12. WONG CH, Leung DK, Gontero P, Teoh JY, et al
    Gene-mediated therapy for BCG-unresponsive nonmuscle-invasive bladder cancer: mechanisms, clinical evidence, and practical implementation.
    Curr Opin Urol. 2025 Sep 19. doi: 10.1097/MOU.0000000000001345.
    PubMed         Abstract available

  13. GABRIEL PE, Horowitz A, Sfakianos JP, Xylinas E, et al
    Targeted therapies for Bacillus Calmette-Guerin unresponsive nonmuscle-invasive bladder cancer: a narrative review.
    Curr Opin Urol. 2025 Sep 19. doi: 10.1097/MOU.0000000000001343.
    PubMed         Abstract available


    Eur Urol

  14. DING D, Qian L, Jin D, Zhou X, et al
    Aptamer-based Positron Emission Tomography Imaging Allows Specific Detection of Residual Bladder Cancer: A First-in-Human Study.
    Eur Urol. 2025 Sep 19:S0302-2838(25)00493-2. doi: 10.1016/j.eururo.2025.
    PubMed        

  15. ZUGMAN M, Carneiro A, Maluf FC
    Challenging the Guidelines: Rethinking Neoadjuvant Therapy for Histologic Subtypes of Bladder Cancer.
    Eur Urol. 2025 Sep 17:S0302-2838(25)00510-X. doi: 10.1016/j.eururo.2025.
    PubMed        

  16. HECK MM, Lehmann J, Amiel T, Rubben H, et al
    Long-term Results from the LEA Randomized Trial: Extended Versus Standard Lymph Node Dissection in Patients with Bladder Cancer Undergoing Radical Cystectomy.
    Eur Urol. 2025 Sep 17:S0302-2838(25)00489-0. doi: 10.1016/j.eururo.2025.
    PubMed         Abstract available


    Eur Urol Oncol

  17. CAO M, Yang G, Zhao T, Zhang L, et al
    Development and Validation of the UriMee Model: A Methylation-based Diagnostic Tool for Early Diagnosis of Urothelial Carcinoma.
    Eur Urol Oncol. 2025;8:899-908.
    PubMed         Abstract available

  18. JAIN RK, Swami U, Bilen MA, Gebrael G, et al
    Cabozantinib plus Pembrolizumab as First-line Therapy for Cisplatin-ineligible Advanced Urothelial Carcinoma: The PemCab Trial.
    Eur Urol Oncol. 2025;8:952-960.
    PubMed         Abstract available

  19. MATSUBARA N, Loriot Y, Banek S, Valderrama BP, et al
    Fibroblast Growth Factor Receptor Alteration Testing for >3600 Patients with Locally Advanced/Metastatic Urothelial Cancer and Non-muscle-invasive Bladder Cancer: An Analysis of the Global ANNAR Biomarker Study.
    Eur Urol Oncol. 2025 Sep 22:S2588-9311(25)00201.
    PubMed         Abstract available

  20. GRIVAS P, Aragon-Ching JB, Bellmunt J, Loriot Y, et al
    Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 Trial.
    Eur Urol Oncol. 2025;8:941-951.
    PubMed         Abstract available


    Eur Urol Open Sci

  21. LIEDBERG F, Hagberg O, Beijert IJ, Aljabery F, et al
    Applicability of the European Association of Urology 2021 Prognostic Model for Non-muscle-invasive Bladder Cancer in a Swedish Population-based Cohort.
    Eur Urol Open Sci. 2025;80:33-37.
    PubMed         Abstract available


    Expert Rev Mol Diagn

  22. LIN N, Zhou Y, Li Y, Lin L, et al
    Circulating tumor DNA and Urinary tumor DNA: useful biomarkers for bladder cancer detection.
    Expert Rev Mol Diagn. 2025 Sep 22. doi: 10.1080/14737159.2025.2565273.
    PubMed         Abstract available


    Front Cell Dev Biol

  23. RUIZ-LORENTE I, Gimeno L, Lopez-Abad A, Lopez Cubillana P, et al
    Interplay of KIR2DL5, nitric oxide, and tobacco smoking in predisposition to bladder cancer.
    Front Cell Dev Biol. 2025;13:1632101.
    PubMed         Abstract available


    Future Sci OA

  24. ZHANG H, Tang K, Chen Y, Chen G, et al
    Downregulated of CTGF reveals mechanism, remodels immune microenvironment, modulates drug sensitivity in bladder cancer.
    Future Sci OA. 2025;11:2560297.
    PubMed         Abstract available


    Gene

  25. BOILLAT S, Goasmat V, Derre L, Domingos-Pereira S, et al
    Role of myeloid-derived suppressor cells in bladder cancer and targeted therapeutic strategies.
    Gene. 2025 Sep 20:149772. doi: 10.1016/j.gene.2025.149772.
    PubMed        


    Hum Mutat

  26. SUN Y, Yi X, Zhou C, Huang Y, et al
    PAQR4: A Critical Senescence-Related Gene Influencing Immune Evasion and Metastasis in Bladder Urothelial Carcinoma.
    Hum Mutat. 2025;2025:2227219.
    PubMed         Abstract available


    Int J Urol


  27. RETRACTION: Astrocyte Elevated Gene-1 Promotes Invasion and Epithelial-Mesenchymal Transition in Bladder Cancer Cells Through Activation of Signal Transducer and Activator of Transcription 3.
    Int J Urol. 2025 Sep 20. doi: 10.1111/iju.70224.
    PubMed         Abstract available


    J Am Soc Cytopathol

  28. VAN TASSEL E, Howell J, Walls K, Crabtree W, et al
    Outcome of atypical urothelial cells (AUC) in patients without prior history of urothelial carcinoma.
    J Am Soc Cytopathol. 2025;14:334-340.
    PubMed         Abstract available


    J Control Release

  29. MIAO Z, Xu A, Shen G, Tang S, et al
    Fluorinated albumin nanocages dually target CAFs and tumor cells to potentiate bladder cancer chemoimmunotherapy.
    J Control Release. 2025;387:114246.
    PubMed         Abstract available


    Oncologist

  30. JANG A, Tripathi N, Lanka SM, Kumar HLS, et al
    Advanced urothelial carcinoma treated with enfortumab vedotin and pembrolizumab: a path to cure?
    Oncologist. 2025;30:oyaf259.
    PubMed         Abstract available


    PLoS One

  31. KATO T, Okauchi N, Motegi T, Sakurai M, et al
    Lactic acid regulates antitumor immunity in canine invasive urothelial carcinoma.
    PLoS One. 2025;20:e0332825.
    PubMed         Abstract available


    Radiologia (Engl Ed)

  32. ETXANO J, Lopez-Maseda A
    Clinical applications of bladder magnetic resonance imaging: Beyond the VI-RADS(R) classification.
    Radiologia (Engl Ed). 2025;67:101668.
    PubMed         Abstract available


    Target Oncol

  33. GRIVAS P, Moon HH
    A Podcast on Real-World Evidence with Avelumab First-Line Maintenance and Treatment Sequencing in Locally Advanced or Metastatic Urothelial Carcinoma.
    Target Oncol. 2025;20:743-754.
    PubMed         Abstract available


    Tissue Cell

  34. ALONSO JCC, Goncalves JM, de Arruda Camargo GC, de Oliveira G, et al
    Dual molecular axis of resistance and immunoresponsiveness to BCG in pT1 non-muscle invasive bladder cancer: Insights from HER-2, SERBP1, HABP4, and IFN-gamma profiling.
    Tissue Cell. 2025;98:103137.
    PubMed         Abstract available


    Urol Oncol

  35. DEL GIUDICE F, Santarelli V, Laszkiewicz J, Li S, et al
    The influence of immunocompromised status on recurrence and progression free survival among nonmuscle invasive bladder cancers (NMIBCs) undergoing transurethral resection of bladder tumor (TURBT) and adjuvant intravesical bacillus Calmette Guerin (BCG
    Urol Oncol. 2025 Sep 19:S1078-1439(25)00254.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.